

# The Kidney in Heart Failure

Natale G. De Santo,\* Massimo Cirillo,\* Alessandra Perna,\* Rosa Maria Pollastro,\* Annamaria Frangiosa,\* Enzo Di Stazio,\* Luigi Iorio,† Vito Andrea Di Leo,\* and Pietro Anastasio\*

Renal dysfunction is a constant feature of congestive heart failure and is a stronger predictor of mortality than left ventricular ejection fraction or New York Heart Association classification. In heart failure, a reduction of glomerular filtration rate and renal plasma flow occurs, although the filtration fraction increases. There are many reasons for this pattern. A reduction in effective circulating volume stimulates sympathetic activity and the renin-angiotensin-aldosterone system, and it is associated with increased concentrations of atrial natriuretic peptide, brain natriuretic peptide, and tumor necrosis factor  $\alpha$ . Because in chronic kidney disease heart dysfunction commonly is present, an efficient cardiologist-nephrologist interaction should be promoted.

Semin Nephrol 25:404-407 © 2005 Elsevier Inc. All rights reserved.

**KEYWORDS** kidney disease, congestive heart failure, renal resistance, GFR, RPF, FF, survival rate, creatinine clearance, cardiologist-nephrologist interaction

The problem of heart failure is an old one. It is even discussed in the *Corpus Hippocraticum*, in which patients with shortness of breath, edema, anasarca, and cardiac cachexia are described.<sup>1</sup> Edema was thought to be caused by a shift of phlegm—a cold humor—from the brain into the chest. This theory persisted for a long time and finally came to an end with Andrea Cesalpino (1571, 1593) and William Harvey (1628).

Katz<sup>2</sup> provided a nice synopsis of the evolution of pathophysiology of heart failure over the past 2500 years. However, we disagree with him in his attribution to Harvey alone of the theory of hemodynamics. In fact, in *Quaestionum peripateticarum* (1571) and in *Quaestionum medicarum* (1593), Andrea Cesalpino of Arezzo (1524-1603) gave an exact demonstration of the general scheme of circulation.<sup>3,4</sup>

The crucial step in understanding the cardiorenal axis is represented by the studies of Starling,<sup>5</sup> who in the lectures to the Royal College of Surgeon in February 1896, stated that “as effect of heart failure sodium retention occurs along with reduced sodium excretion. Continuous increase in circulating fluid occurs till capillary pressure is restored.” However, in 1931 Wollheim gave the first demonstration that blood

volume increases with heart failure and edema, and in 1935 Peters<sup>6</sup> noted that “the kidneys react to changes of circulating blood but are indifferent to changes in the volume of body fluids.” Shortly thereafter, it also became clear that in “heart disease there is inadequate translocation of fluid from venous to arterial side,”<sup>7</sup> and that the link between inadequate filling of the systemic arterial tree and edema formation is brought up by the kidneys.<sup>8</sup>

However, as pointed out by Anand,<sup>9</sup> “the effective blood volume is a poorly defined entity because there are no known mechanisms by which the body can directly monitor its inadequacy and it cannot be measured. Until we can measure effective blood volume this concept must remain hypothetical.”

We now know that a reduction of effective circulating volume stimulates catecholamines, angiotensin II, endothelin, and anti diuretic hormone (ADH), which cause reduction of renal blood flow (RBF), glomerular filtration rate (GFR), and an increase of filtration fraction (FF). An increase in proximal reabsorption occurs, followed by reduced distal sodium delivery and activation of the juxtaglomerular apparatus.<sup>10</sup>


In 1946, Merrill<sup>11</sup> was the first to measure GFR and renal plasma flow (RPF) in heart failure (Fig 1) and it was evident that RPF was more affected than GFR. The information was confirmed by Aas and Blegen.<sup>12</sup> However, it took many more years and the advent of micropuncture techniques to understand the underlying tubular and glomerular mechanisms.<sup>13,14</sup>

\*First Division of Nephrology Second University of Naples, Naples, Italy.

†Division of Nephrology, “De Bosis” Hospital, Cassino, Italy.

Supported by Regione Campania.

Address reprint requests to Natale G. De Santo, MD, 5 Via Pansini, Pad 17, First Division of Nephrology, Second University of Naples, 80131 Naples, Italy. E-mail: nataleg.desanto@unina2.it



**Figure 1** GFR, RPF, and FF. ■, control; □, CHF. Data from Merrill.<sup>11</sup>

## Two Suicides

Andreoli<sup>15</sup> has shown nicely that in conditions of underfilling, similar to those occurring in systolic pump failure, a suicidal arterial filling takes place. In fact, because of the hemodynamic changes, there is an increase in afterload that leads to an increased end-diastolic volume. However, underfilling affects sodium avidity, thus increasing preload and causing an increase in end-diastolic volume, which reduces the ejection fraction.

The second suicide occurs via tumor necrosis factor  $\alpha$ , which triggers apoptosis, increases nitric oxide, and enhances expression of proto-oncogenes. The synthesis of a locally active cytokine induces the heart to commit suicide at the molecular level.<sup>16</sup> In fact, tumor necrosis factor  $\alpha$  causes cachexia, anorexia, and inflammation.

## Neurohormonal Activation

Although kidney dysfunction at the present time is considered a general feature of congestive heart failure (CHF) it still is undecided<sup>17</sup> if it should be considered as a comorbidity or a maladaptation that induces changes of fluid regulation and the renin-angiotensin-aldosterone system (RAAS).

In CHF, significant changes occur in the cardiorenal axis, which operates under the control of the RAAS (sodium retaining, antidiuretic, vasoconstricting, and profibrotic), and of a group of peptides (atrial natriuretic peptide [ANP], brain natriuretic peptide [BNP], and C-type natriuretic peptide [CNP]). ANP and BNP, released by myocardial cells of the heart, and CNP, released by the endothelium, are natriuretic, diuretic, vasodilating, inhibitory for renin and aldosterone, and antifibrotic. In this context, ANP and BNP are seen as diuretic hormones secreted in response to stretch. ANP and BNP operate through guanylated cyclase A receptors, whereas CNP operates through a guanylate cyclase B receptor. All of them are bound to a clearance receptor that metabolizes them through the neutral endopeptidase. Blockade of neutral endopeptidase–receptor results in reduced GFR

and reduced sodium excretion. ANP and BNP are considered markers of heart failure. BNP has a greater specificity and may be used for diagnostic purposes. It has been shown that in patients undergoing a 40% reduction of BNP concentration during treatment, this feature is associated with 1 class decrease in New York Heart Association (NYHA) classification of heart failure.<sup>17</sup>

Aldosterone is sodium retaining and potassium wasting, by acting on Nedd4, which causes sodium reabsorption. In CHF an aldosterone escape failure occurs, and aldosterone antagonists have many beneficial effects on sodium balance and heart fibrosis.<sup>18</sup>

ANP and BNP increase GFR by increasing glomerular hydrostatic pressure and Kf, decrease proximal and distal sodium reabsorption, increase blood flow in vasa recta, and decrease renin release. ANP and BNP blood concentrations are increased significantly in CHF. A decreased response to ANP has been shown in human beings with CHF. Hyporesponsiveness is of multifactorial origin, and includes a reduction of renal perfusion pressure and an increase in renal sympathetic activity. Finally, it should be stressed that in CHF the kidneys are normal, and, when transplanted in healthy individuals, they operate normally.

Taken together, the neurohormonal response activated in CHF is identical to that which occurs after physical exercise or hemorrhage.<sup>19,20</sup> A response evolved over the millennia to resist those life-threatening conditions such as hemorrhage and physical exercise. Under these conditions there is an increased sympathetic activity with vasoconstriction, tachycardia, myocardial stimulation, and regional vasoconstriction.<sup>9</sup> Additionally, in CHF the threat to blood pressure is long lasting, therefore the effector mechanism is operating continuously, thus the unloading of high-pressure baroreceptors stimulate sympathetic activity, as well as the RAAS and Arginine Vasopressin (AVP).

## GFR and Starling Forces

The transcapillary hydrostatic pressure ( $\Delta P$ ) slowly decreases along the capillary length both in health and heart failure. However, in CHF it is much higher than in normal patients because of efferent arterial vasoconstriction. The transmural oncotic pressure ( $\Delta \pi$ ) increases over the capillary length both in normal patients and patients with CHF. However, in CHF it also is higher because of the increase in FF. This situation is brought about by a disproportionate increase in efferent vasoconstriction that protects GFR.

Along the peritubular capillary,  $\Delta P$  is reduced more than in normal subjects. However,  $\Delta \pi$  is higher, thus the driving force ( $\Delta P - \Delta \pi$ ) enhances proximal reabsorption of sodium and water. However, in CHF the changes in intrarenal hemodynamics, the sympathetic stimulation, and the stimulation of angiotensin II also may promote sodium reabsorption in Henle's loop.<sup>21</sup>

The afferent to efferent balance is shown in Figure 2, which gives a synopsis of RBF and GFR in treated and untreated heart failure patients.<sup>22</sup> It should be added that patients with end-stage heart failure treated with angiotensin-converting

enzyme (ACE) inhibitors have a normal renal reserve<sup>23</sup> even in the presence of a reduction in GFR and RPF associated with enhanced FF (Fig 3). This also happens in mild CHF (grade I NYHA) in which ACE inhibitors reinstate a renal reserve after infusion of amino acids.<sup>24</sup>


## Renal Function and Survival in CHF

It is a common notion that in CHF survival depends on plasma sodium potassium and magnesium levels.<sup>25,26</sup> Even blood urea, considered an unreliable index of renal function, can predict survival. Renal function is the most powerful predictor of mortality.<sup>27</sup> A study in 1,906 patients with a creatinine clearance level less than 44 mL/min (calculated by means of the Cockcroft and Gault equation) had a mortality risk of 2.85 in comparison with those patients with a creatinine clearance of more than 76 mL/min ( $P < .001$ ). The study also showed that creatinine clearance is a stronger predictor of mortality than left ventricular ejection fraction or NYHA class and strongly correlated with N-terminal ANP.<sup>27</sup>


## Nephrologist-Cardiologist Interaction

There is a general quest from patients with heart disease and from patients with kidney disease for a nephrologist-cardiologist interaction. This also is stressed nicely by Packer<sup>28</sup>:

As medicine is practiced in the 1990s the patients with heart disease and renal disease (whether these disorders are seen in the same patient or in different patients) are frequently managed by physicians who are interested in only one of the two organ systems. Under the rare circumstances, when the patient is visited by both types of specialists, the physicians take frequently opposite point of view and make therapeutic recommendations that are principally designed to preserve the function as a single organ system (that is the



**Figure 2** Afferent to efferent in different groups of patients with end stage heart failure (HF), also given ACE inhibitors (ACEi). Modified from Leier and Boudoulas.<sup>22</sup>



**Figure 3** Renal reserve in patients with end stage heart failure waiting for heart transplantation. ■, control; □, CHF. Data from Frangiosa et al.<sup>23</sup>

focus of the physician's specialty). Since kidneys play an important role in heart disease and the heart plays a role in all patients with renal disease, cardiorenal interactions are becoming more and more important.<sup>21</sup>

## References

- De Santo NG, Touwaide A: Edema in the *Corpus Hippocraticum*. *Am J Nephrol* 19:155-158, 1999
- Katz AM: Evolving concepts of the pathophysiology of heart failure, in Mann DL (ed): *Heart Failure*. Philadelphia, Saunders, 1904, pp 1-9
- Arcieri JP: The circulation of the blood and Andrea Cesalpino of Arezzo. New York, F.S. Vanni, 1945, p 47
- Willius FA, Dry TJ: The heart and the circulation. Philadelphia, Saunders, 1948, pp 43-44
- Starling EH: Physiological factors involved in the causation of dropsy. *Lancet* 1:1407-1419, 1986
- Peters JP: *Body water*. Springfield, IL, Charles C. Thomas Publishers, 1935
- Stead EA Jr, Ebert RV: Shock syndrome produced by failure of the heart. *Arch Intern Med* 69:75-89, 1942
- Warren JV, Stead EA Jr: Fluid dynamics in chronic congestive heart failure. *Arch Intern Med* 73:138-147, 1944
- Anand IS: Pathogenesis of salt and water retention in the congestive heart failure syndrome, in Poole-Wilson PA, Colucci WS, Massie BM, et al (eds): *Heart Failure*. New York, Churchill Livingstone, 1997, pp 155-171
- Andreoli TE: Edematous states: An overview. *Kidney* 51:S11-S15, 1997 (suppl 59)
- Merrill AJ: Edema and decreased renal blood flow in patients with chronic congestive heart failure: Evidence of "forward failure" as the primary cause of edema. *J Clin Invest* 25:389-400, 1946
- Aas K, Blegen E: The renal blood flow and the glomerular filtration rate in congestive heart failure and some other clinical conditions. *Scand J Clin Invest* 1:22-24, 1949
- Ichikawa I, Pfeffer JM, Pfeffer MA, et al: Role of angiotensin II in the altered renal function of congestive heart failure. *Circ Res* 55:669-675, 1984
- Kircheim H, Ehmke H, Hackenthal E, et al: Autoregulation of renal blood flow, glomerular filtration rate and renin release in conscious dogs. *Am J Cardiol* 410:411-449, 1987
- Andreoli TE: Pathogenesis of renal sodium retention in congestive heart failure. *Miner Electrolyte Metab* 25:11-20, 1999
- Packer M: Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? *Circulation* 39:1379-1382, 1995

17. Burnett JC Jr, Costello-Boerrigter L, Boerrigter G: Alteration of the kidney in heart failure. The cardiorenal axis in the regulation of sodium homeostasis, in Mann DL (ed): Heart Failure. Philadelphia, Saunders, 2004
18. Lee SC, Stevens TL, Sandberg SM, et al: The potential of BNP as a biomarker for NYHA class during the outpatients treatment of heart failure. *J Card Fail* 8:149-154, 2002
19. Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 341:709-717, 1999
20. Harris P: Congestive cardiac failure. Central role of arterial blood pressure. *Br Heart J* 58:190-203, 1987
21. Harris P: Role of arterial blood pressure in oedema of heart disease. *Lancet* 1:1036-1038, 1988
22. Leier CV, Boudoulas H: *Cardiorenal disease and disorders*. Houston, Futura Publishing Company, 1992
23. Frangiosa A, Spitali L, Molino D, et al: Renal reserve is normal in patients with dilative cardiomyopathy waiting for heart transplantation. *Miner Electrolyte Metab* 25:24-27, 1999
24. Magri P, Rao MA, Cangianiello S, et al: *Circulation* 98:2849-2854, 1998
25. Leier CV, Del Cas L, Metra M: Clinical relevance and management of the major electrolyte abnormalities in heart failure: Hyponatremia, hypokalemia and hypomagnesemia. *Am Heart J* 128:364-374, 1994
26. Parameshawar J, Keega J, Sparrow J, et al: Predictors of prognosis in severe heart failure. *Br Heart J* 74:341-342, 1993
27. Hillege HL, Girbes ARJ, de Kam PJ, et al: Renal function, neurohormonal activation and survival in patients with chronic heart failure. *Circulation* 102:203-210, 2000
28. Packer M: Foreword, in Leier CV, Boudoulas H (eds): *Cardiorenal Diseases and Disorders*. Houston, Futura Publishing Company, 1992, p IV